Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 464 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Expansion Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: Ramucirumab, Necitumumab, Osimertinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: NHL, NHL, Relapsed, Adult
Interventions: CLN-978; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 3 more

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: piflufolastat F 18; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: St Louis, Missouri • Omaha, Nebraska

Conditions: Oral Cavity Squamous Cell Carcinoma
Interventions: NisinZ® P, Surgery (non-interventional, standard of care); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced and/or Metastatic Solid Tumours
Interventions: CB307; Drug
Lead sponsor: Crescendo Biologics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Interventions: YH42946; Drug
Lead sponsor: Yuhan Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
Interventions: SB-007; Genetic
Lead sponsor: Splice Bio; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel; Biological · Other · Drug
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more

Conditions: TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP); Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 20
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more

Conditions: Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
Interventions: S227928, Venetoclax; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 5
States / cities: Duarte, California • Fairway, Kansas • Grand Rapids, Michigan + 2 more

Conditions: Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
Interventions: Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Liver Cancer, Lung Cancer
Interventions: Ipilimumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms
Interventions: FdCyd + THU; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 6
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 3 more

Conditions: NSCLC, Gastric Cancer
Interventions: PEGPH20, Pembrolizumab; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 28
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 25 more

Conditions: Neoplasms by Site
Interventions: Denenicokin, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more

Conditions: Neuroblastoma
Interventions: Hu3F8 With GM-CSF; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma
Interventions: GEN3009, Epcoritamab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Denver, Colorado • Cleveland, Ohio • Columbus, Ohio + 4 more

Conditions: Geographic Atrophy
Interventions: OCU410; Genetic
Lead sponsor: Ocugen; Industry
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 12
States / cities: Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more

Conditions: Advanced Solid Tumors
Interventions: FORX-428; Drug
Lead sponsor: FoRx Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more

Conditions: Solid Tumor
Interventions: STP707; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more

Conditions: Breast Cancer
Interventions: Olaparib, Carboplatin, Anthracycline, Cyclophosphamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: New York, New York • Stony Brook, New York

Conditions: Prostatic Neoplasms, Prostatic Cancer
Interventions: ETBX-071; adenoviral PSA vaccine, ETBX-061; adenoviral MUC1 vaccine, ETBX-051; adenoviral brachyury vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Myeloid
Interventions: CC-90011, Venetoclax, Azacitidine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Duarte, California • New Haven, Connecticut • Miami, Florida + 8 more

Conditions: Multiple Myeloma
Interventions: TNB-383B; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: San Francisco, California • New Orleans, Louisiana • Rochester, Minnesota + 6 more

Search by objective public record fields.

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors

FdCyd and THU for Advanced Solid Tumors

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma